Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Julphar
McKesson
Colorcon
Harvard Business School
Moodys
US Army
Fuji
Deloitte
Boehringer Ingelheim

Generated: October 23, 2017

DrugPatentWatch Database Preview

KYTRIL Drug Profile

« Back to Dashboard

Which patents cover Kytril, and when can generic versions of Kytril launch?

Kytril is a drug marketed by Roche and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-six patent family members in nineteen countries.

The generic ingredient in KYTRIL is granisetron hydrochloride. There are twenty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.

Summary for Tradename: KYTRIL

US Patents:1
Applicants:1
NDAs:3
Bulk Api Vendors: see list63
Clinical Trials: see list16
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KYTRIL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche
KYTRIL
granisetron hydrochloride
TABLET;ORAL020305-001Mar 16, 1995DISCNYesNo► Subscribe► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-002Mar 11, 1994DISCNYesNo► Subscribe► Subscribe ► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-003Sep 17, 2004DISCNYesNo► Subscribe► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
TABLET;ORAL020305-002Jun 15, 1998DISCNYesNo► Subscribe► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
SOLUTION;ORAL021238-001Jun 27, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-001Dec 29, 1993DISCNYesNo► Subscribe► Subscribe ► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-004Mar 11, 1994DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KYTRIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche
KYTRIL
granisetron hydrochloride
TABLET;ORAL020305-001Mar 16, 1995► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-002Mar 11, 1994► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-001Dec 29, 1993► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-004Mar 11, 1994► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
SOLUTION;ORAL021238-001Jun 27, 2001► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-004Mar 11, 1994► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-001Dec 29, 1993► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
TABLET;ORAL020305-002Jun 15, 1998► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-003Sep 17, 2004► Subscribe► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-002Mar 11, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for KYTRIL

Drugname Dosage Strength RLD Submissiondate
granisetron hydrochlorideInjection0.1 mg/mL, 1 mL single dose vialKytril3/8/2007
granisetron hydrochlorideInjection1 mg/mL, 4 mL multi-dose vialsKytril7/19/2004
granisetron hydrochlorideInjection1 mg/mL, 1 mL vialsKytril6/1/2004

International Patent Family for Tradename: KYTRIL

Country Document Number Estimated Expiration
Israel109059► Subscribe
Japan3792251► Subscribe
European Patent Office0689437► Subscribe
Cyprus2427► Subscribe
Hungary214629► Subscribe
Australia6377494► Subscribe
African Regional IP Organization (ARIPO)511► Subscribe
United Kingdom9305593► Subscribe
Taiwan312622► Subscribe
South Africa9401844► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
QuintilesIMS
Argus Health
Johnson and Johnson
Boehringer Ingelheim
Healthtrust
Queensland Health
Merck
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot